Soligenix (SNGX) Convertible Debt (2020 - 2024)
Soligenix's (SNGX) quarterly Convertible Debt came in at $2.1 million in Q3 2024, down 29.39% YoY from $2.9 million in Q4 2023, and down 25.0% on a QoQ basis from $2.7 million in Q2 2024.
Soligenix (SNGX) Convertible Debt (2020 - 2024) Analysis & Trends
Soligenix (SNGX) has 5 years of Convertible Debt data on file, last reported at $2.1 million in Q3 2024.
- Quarterly Convertible Debt fell 29.39% year-over-year to $2.1 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $2.1 million (down 29.39% YoY) and the FY2023 annual result came in at $3.3 million, changed N/A from the prior year.
- Convertible Debt fell to $2.1 million in Q3 2024, from $2.7 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $10.0 million in Q1 2021 to a low of $2.1 million in Q3 2024.
- A 5-year average of $6.3 million and a median of $6.9 million in 2022 frame the typical range for Convertible Debt.
- Annual changes were most pronounced in 2023 — Convertible Debt plunged 70.53% — and 2024, when it grew 3.03%.
- Tracing SNGX's Convertible Debt over 5 years: stood at $9.9 million in 2020, then fell by 0.04% to $9.9 million in 2021, then sank by 30.12% to $6.9 million in 2022, then sank by 52.65% to $3.3 million in 2023, then plunged by 36.85% to $2.1 million in 2024.
- The last three Convertible Debt figures came in at $2.1 million (Q3 2024), $2.7 million (Q2 2024), and $3.0 million (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Soligenix | 6.31 Mn | 6.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 2.75 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 3.26 Mn |
| Sep 30, 2023 | 2.92 Mn |
| Jun 30, 2023 | 2.84 Mn |
| Mar 31, 2023 | 2.91 Mn |
| Sep 30, 2022 | 6.89 Mn |
| Jun 30, 2022 | 7.88 Mn |
| Mar 31, 2022 | 9.87 Mn |
| Dec 31, 2021 | 9.86 Mn |
| Sep 30, 2021 | 9.85 Mn |
| Jun 30, 2021 | 9.84 Mn |
| Mar 31, 2021 | 10.00 Mn |
| Dec 31, 2020 | 9.86 Mn |